Boehringer Ingelheim Gmbh

Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Peter Meindl

Peter Swetly

Gerhard Bodo

Gunther R Adolf

Rudolf Hauptmann

Ingrid Maurer-Fogy

Edgar Falkner

Ernest Cullen

Hans Tuppy

Silvia J Lindner-Frimmel

Eva Dworkin-Rastl

This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,

Hybrid interferons, their use as pharmaceutical compositions and as

A novel species of alpha interferon is taught. The alpha interferon amino acid sequence is disclosed and a gene corresponding thereto. The alpha interferon gene is expressed in Escherichia coli.

Novel alpha interferon species produced by recombinant means

This invention is directed to a process of producing interferon which comprises incubating permanent cell lines of lymphoblast origin or human fibroblast cells with interferon inducers and stimulator substances and recovering the interferon produced.

Process for the production of human interferon

Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl,

3,6-Bis-(heterocyclic aminoacyl-amino)-acridines and salts thereof

Growing community of inventors

Vienna, Austria

Peter Meindl